Physician profile
Cheri Frey
NPI 1033401898
$78,785.73
in general payments reported to CMS, 2019-2025
30 companies · $43K in 2025
The $43K reported for 2025 was more than what 96% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $796 · 2020: $73.16 · 2021: $78.70 · 2022: $7,250 · 2023: $10K · 2024: $18K · 2025: $43K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $54K · Food and Beverage: $6,404 · Travel and Lodging: $5,838 · Education: $4,509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $53,836.50 |
| Food and Beverage | $6,403.67 |
| Travel and Lodging | $5,838.01 |
| Education | $4,509.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $18,649.91 | 2023-2025 | Opzelura, Opzelura |
| Sun Pharmaceutical Industries INC. | $13,961.48 | 2022-2025 | Absorica Ld, Winlevi |
| Regeneron Healthcare Solutions, INC. | $12,651.14 | 2019-2025 | Dupixent |
| Abbvie INC. | $9,123.84 | 2019-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $6,194.12 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $5,990.48 | 2022-2025 | Sotyktu |
| Revance Therapeutics, INC. | $2,546.01 | 2025 | Daxxify |
| Ucb, INC. | $2,120.65 | 2022-2025 | Bimzelx |
| Janssen Scientific Affairs, LLC | $2,049.49 | 2025 | Tremfya |
| Avita Medical Americas, LLC | $1,500.00 | 2023 | Recell |
| Pfizer INC. | $1,337.32 | 2019-2025 | |
| Galderma Laboratories, L.P. | $808.00 | 2019-2025 | Nemluvio, Aklief |
| Janssen Biotech, INC. | $247.02 | 2019-2025 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $203.05 | 2019-2025 | Cabtreo, Siliq |
| Merz North America, INC. | $200.48 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Solta Medical, A Division of Bausch Health US, LLC | $181.73 | 2023 | |
| Almirall LLC | $152.05 | 2019-2025 | Seysara |
| Leo Pharma INC. | $130.43 | 2019-2022 | |
| Allergan, INC. | $123.49 | 2019 | |
| Dermavant Sciences, INC. | $113.14 | 2024 | Vtama |
| Genzyme Corporation | $96.77 | 2019 | |
| Abiomed | $62.72 | 2024 | Impella |
| Eli Lilly and Company | $62.02 | 2022 | |
| Lilly USA, LLC | $56.50 | 2019-2023 | Olumiant |
| Mayne Pharma Commercial LLC | $55.20 | 2019-2020 | |
| Arcutis Biotherapeutics, INC. | $49.38 | 2025 | Zoryve |
| Encore Dermatology INC. | $39.86 | 2019 | |
| Amgen INC. | $34.17 | 2022 | |
| Novum Pharma, LLC | $25.00 | 2019 | |
| Convatec INC. | $20.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheri Frey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.